Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The readiness of Vγ9Vδ2 T-cell immunotherapy for widespread use in treating blood cancers is being considered. The question of whether this treatment is ready for prime time is being raised. The status of Vγ9Vδ2 T-cell immunotherapy in blood cancer treatment is uncertain.